Drug-induced peripheral neuropathy

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 2, 2014, Pages 185-192

  Vilholm, Ole Jakob ^a   Christensen, Alex Alban ^a   Zedan, Ahmed Hussein ^a   Itani, Mustapha ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICALLY INDUCED; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; OPTIC NERVE DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; OPTIC NERVE DISEASES; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84904395318     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12261     Document Type: Review

References (64)

1. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005;18:574-80.
2. Stübgen JP. Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci 2011;307:1-8.
3. Toyooka K, Fujimura H. Iatrogenic neuropathies. Curr Opin Neurol 2009;22:475-9.
4. Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003;3:86-92.
5. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27-46.
6. Gaist D, Jeppesen U, Andersen M, Rodriguez G, Hallas J, Sindrup SH. Statins and risk of polyneuropathy. Neurology 2002;58:1333-7.
7. Corrao G, Zambon A, Bertù L, Botteri E, Leoni O, Contiero P. Lipid-lowering drugs prescription and the risk of peripheral neuropathy an exploratory case-control study using automated databases. J Epidemiol Community Health 2004;58:1047-51.
8. de Langen JJ, van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med 2006;64:334-8.
9. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-83.
10. Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34:669-71.
11. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66:865-9.
12. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 1969;19:367-74.
13. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973;96:69-86.
14. Pace A, Bove L, Nisticò C, Ranuzzi M, Innocenti P, Pietrangeli A et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996;61:409-11.
15. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005;41:1460-6.
16. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28.
17. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42.
18. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS ONE 2011;6:e18469.
19. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008;9:463-72.
20. Van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;66:1697-702.
21. Gurney H, Crowther D, Anderson H, Murphy D, Prendville J, Ranson M et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol 1990;1:427-33.
22. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593-9.
23. Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003;60:877-8.
24. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275-82.
25. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042-9.
26. Litzow MR. Arsenic trioxide. Expert Opin Pharmacother 2008;9:1773-85.
27. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010;24:655-67.
28. van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 2011;15:722-8.
29. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010;24(Suppl 5):29-36.
30. Fraunfelder FW, Sadun AA, Wood T. Update on ethambutol optic neuropathy. Expert Opin Drug Saf 2006;5:615-8.
31. Legout L, Valette M, Dezeque H, Sophie N, Lemaire X, Loïez C et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010;65:2224-30.
32. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.
33. Park IN, Hong SB, Oh Y-M, Kim M-N, Lim C-M, Lee SD et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.
34. Shin SS, Hyson AM, Castaneda C, Sánchez E, Alcántera F, Mitnick CD et al. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2003;7:347-53.
35. Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Inf Dis Suppl 1981;26:60-7.
36. Shen B, Achkar J-P, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-5.
37. Lance George W, Kirby BD, Sutter VL, Wheeler LA, Mulligan ME, Finegold SM. Intravenous metronidazole for treatment of infections involving anaerobic bacteria. Antimicrob Agents Chemother 1982;21:441-9.
38. Duffy LF, Daum F, Fisher SE, Selman J, Vishnubhakat SM, Aiges HW et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88:681-4.
39. Ståhlberg D, Bárány F, Einarsson K, Ursing B, Elmqvist D, Persson A. Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole. Scand J Gastroenterol 1991;26:219-24.
40. Yiannakis C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy. Aust N Z J Med 1981;11:400-5.
41. Sharafadinzadeh N, Moghtaderi A, Alavi-Naini R. Nitrofurantoin-induced peripheral neuropathy: a lesson to be re-learnt. Neurol India 2008;56:94-6.
42. Penn R, Griffin J. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J 1982;284:1440-2.
43. Tan I, Polydefkis J, Ebenezer G, Hauer P, McArthur J. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012;69:265-8.
44. Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37:81-292.
45. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-91.
46. Shin I-SJ, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre′ and Miller Fisher syndromes occurring with tumor necrosis factor-antagonist therapy. Arthritis Rheum 2006;54:1429-34.
47. Latov N, Sherman WH. Improvement with etanercept (Enbrel) in chronic inflammatory demyelinating polyneuropathy [abstract]. Ann Neurol 2000;48:473.
48. Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21.
49. Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori T. Serum levels of tumor necrosis factor-α in chronic inflammatory demyelinating polyneuropathy. Neurology 2001;56:666-9.
50. Kato-Motozaki Y, Komai K, Takahashi K, Ishida C, Ueda M, Kusunoki S et al. Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy. Intern Med 2009;48:569-72.
51. Shiga K, Tanaka E, Isayama R, Mizuno T, Itoh K, Nakagawa M. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon α-2b: a neuropathology case report. Intern Med 2012;51:217-21.
52. Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology 2004;43:934.
53. Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007;37:101-7.
54. Martin K, Bentaberry F, Dumoulin C, Miremont-Salamé G, Haramburu F, Dehais J et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007;16:74-8.
55. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998;19:481-94.
56. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011;11:244.
57. Wadley AL, Cherry CL, Price P, Kamerman PR. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage 2011;41:700-6.
58. Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A et al. Levodopa, Methylmalonic acid, and Neuropathy in Idiopathic Parkinson disease. Ann Neurol 2010;67:28-36.
59. Rajabelly A, Martey J. Neuropathy in Parkinson disease. Neurology 2011;77:1947-50.
60. Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M. Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy 2010;30:661-5.
61. Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother 2011;66:2136-9.
62. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS et al. A new definition of neuropathic pain. Pain 2011;152:2204-5.
63. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81.
64. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88.